Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217.

ABSTRACT:

Background

Recent advances in disease-modifying treatments highlight the need for accurately identifying individuals in early Alzheimer's disease (AD) stages and for monitoring of treatment effects. Plasma measurements of phosphorylated tau (p-tau) are a promising biomarker for AD, but different assays show varying diagnostic and prognostic accuracies. The objective of this study was to determine the clinical performance of a novel plasma p-tau217 (p-tau217) assay, p-tau217+_Janssen, and perform a head-to-head comparison to an established assay, plasma p-tau217_Lilly, within two independent cohorts_. METHODS: The study consisted of two cohorts, cohort 1 (27 controls and 25 individuals with mild-cognitive impairment [MCI]) and cohort 2 including 147 ind

SUBMITTER: Groot C 

PROVIDER: S-EPMC9107269 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature